The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Kyverna Therapeutics Inc. ...

NEW YORK, Jan. 16, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX).Shareholders who purchased shares of KYTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/kyverna-therapeutics-inc-loss-submission-form/?id=123047&from=4CLASS PERIOD: T ...

Please check back later to see all of our exciting changes. ...

Core Viewpoint - The Gross Law Firm is notifying shareholders of Kyverna Therapeutics, Inc. regarding a class action lawsuit related to the company's initial public offering (IPO) in February 2024, alleging misleading statements and omissions in the offering documents [1][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals who purchased or acquired Kyverna common stock during the class period associated with the February 2024 IPO [3]. - Allegations include that the defendants issued materially false and misleading statements and failed to disclose critical information regarding the IPO strategy, terms, and disclosures in the offering documents [4]. - The complaint suggests that the underwriter defendants should have been aware of Kyverna's undisclosed issues due to ongoing communications with the company's management and legal representatives [4]. Group 2: Shareholder Actions - Shareholders are encouraged to register for the class action by February 7, 2025, to participate in potential recovery [5]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [5]. - There is no cost or obligation for shareholders to participate in the lawsuit [5]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [6]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [6].

Extending Company's leadership position in autoimmune CAR T with prioritized indication strategy; pivoting to late-stage development and commercialization First-to-market opportunity with KYV-101 in stiff person syndrome; 40% enrolled in pivotal Phase 2 trial with first BLA filing targeted for 2026; fast-follow indications in myasthenia gravis and lupus nephritis Efficiently expanding into broader autoimmune indications and increasing patient reach with KYV-102 using whole blood rapid manufacturing Cash run ...

NEW YORK, Jan. 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX).Shareholders who purchased shares of KYTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/kyverna-therapeutics-inc-loss-submission-form/?id=121991&from=4CLASS PERIOD: T ...

Core Viewpoint - A securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. for allegedly making materially false and misleading statements in connection with its February 8, 2024 IPO [1][2]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Kyverna common stock during its IPO [1]. - The lead plaintiff deadline for the lawsuit is set for February 7, 2025 [1][3]. - The complaint alleges that Kyverna failed to disclose adverse data related to one of its clinical trials at the time of the IPO [2]. Group 2: Lead Plaintiff Process - Investors may seek to be appointed as a lead plaintiff representative of the class by the deadline or may choose to remain absent [3]. - The lead plaintiff is typically the investor or small group of investors with the largest financial interest in the case [3]. Group 3: Law Firm Background - Kessler Topaz Meltzer & Check, LLP has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [4].

Core Viewpoint - A class action has been filed against Kyverna Therapeutics, Inc. for allegedly providing misleading information in its IPO documents, leading to a significant decline in share price [1][2][3]. Group 1: Allegations and Legal Action - The complaint claims that the Offering Documents for Kyverna's IPO were negligently prepared and did not comply with regulatory standards [2]. - Specific statements in the Offering Documents regarding trial results were deemed false and misleading due to the omission of adverse data [2]. - By the time the action commenced, Kyverna's shares had dropped to $3.92, representing an over 82% decline from the IPO offering price [3]. Group 2: Class Action Participation - Shareholders interested in serving as lead plaintiffs must submit their applications by February 7, 2025 [4]. - Participation in the class action is not mandatory for recovery; shareholders can remain absent class members if they choose [4]. Group 3: Company Background - Kyverna Therapeutics is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases [1].

NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Kyverna Therapeutics, Inc. ("Kyverna Therapeutics, Inc." or the "Company") (NASDAQ: KYTX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Kyverna Therapeutics, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all those who purchased or otherwise acquired Kyverna common stock pursuant and/or traceable to the Company's of ...

Core Viewpoint - Investors in Kyverna Therapeutics, Inc. have the opportunity to lead a securities fraud class action lawsuit due to substantial losses incurred following the company's initial public offering in February 2024 [1][3]. Group 1: Lawsuit Details - The lawsuit alleges that Kyverna Therapeutics failed to disclose adverse data related to one of its clinical trials, which misled investors regarding the company's business and operational prospects [3]. - The complaint highlights that the defendants' positive statements about the company's performance lacked a reasonable basis due to the withholding of critical adverse data [3]. Group 2: Participation Information - Investors who suffered losses in Kyverna Therapeutics are encouraged to contact the Law Offices of Howard G. Smith before February 7, 2025, to participate in the ongoing lawsuit [2][4]. - Individuals interested in learning more about the class action or their rights can reach out to the law firm via email or phone [4][5].